Life Sciences

  • February 23, 2026

    Zynex Faces Securities Suit Following Arrest Of Former Execs

    After being arrested last month on charges of securities fraud and conspiracy, the former CEO and ex-chief compliance officer of bankrupt medical device maker Zynex have been hit with a securities class action that alleges they and others caused the company to engage in fraudulent billing practices that inflated its stock price and led to investor losses once the truth came to light.

  • February 23, 2026

    Synthego Urges Justices To Reject AI Bait In CRISPR Case

    Synthego Corp. has called for the U.S. Supreme Court to turn away Agilent Technologies Inc.'s appeal of its invalidated CRISPR patents, saying the patent owner is inappropriately leveraging artificial intelligence to make the case sound more pressing than it is.

  • February 23, 2026

    CBP Clears Redesigned Tourniquet Imports After IP Ban

    U.S. Customs and Border Protection has found that a modified version of a tourniquet made by a Chinese company isn't subject to an import ban issued by the U.S. International Trade Commission after finding that earlier imports infringed a patent.

  • February 23, 2026

    Corcept Mischaracterized Drug Approval Odds, Investor Says

    Pharmaceutical company Corcept Therapeutics Inc. faces a proposed investor class action alleging it overstated approval prospects for a Cushing's syndrome drug candidate, hurting investors when its trading prices halved after it disclosed the U.S. Food and Drug Administration wouldn't accept the approval bid.

  • February 23, 2026

    Philly-Area Fertility Clinic Settles Patient's Acid Burn Suit

    A woman who sued a fertility clinic for allegedly mistakenly injecting her uterine cavity with acid, which she said caused her to suffer second-degree burns, has settled her lawsuit against the clinic for an undisclosed amount.

  • February 23, 2026

    Justices Want Natera's Take On CareDx's False Ad Petition

    The U.S. Supreme Court on Monday asked for Natera's position on a petition from rival CareDx asking the high court to review a Third Circuit decision that erased a $45 million jury award stemming from CareDx's false advertising claims.

  • February 23, 2026

    Asthma Biotech Generate Biomedicines Eyes $400M IPO

    Asthma-focused biotech firm Generate Biomedicines on Monday filed plans with U.S. regulators to raise around $400 million in its initial public offering led by Goodwin Procter LLP and Latham & Watkins LLP.

  • February 23, 2026

    Life Sciences Group Of The Year: Ropes & Gray

    Ropes & Gray LLP guided Gilgamesh Pharmaceuticals in a potentially $1.2 billion deal with AbbVie and advised Novo Nordisk in eight licensing and mergers and acquisitions transactions for novel obesity and metabolic disease treatments, earning the firm a spot among the 2025 Law360 Life Sciences Group of the Year.

  • February 23, 2026

    Hims & Hers Misleads With GLP-1 Claims In Ads, Court Told

    A class of GLP-1 patients claim that telehealth company Hims & Hers falsely advertised its compounded injections as made with "the same active ingredient" as weight loss drugs Ozempic and Wegovy despite containing other key ingredients, according to a suit filed in Illinois federal court. 

  • February 23, 2026

    Ropes, Wilson Sonsini Guide Gilead's $7.8B Arcellx Buy

    Gilead Sciences Inc. announced Monday that it has agreed to acquire clinical-stage biotechnology company Arcellx Inc. for $115 per share in cash plus one contingent value right worth $5 per share, reflecting an implied equity value of $7.8 billion.

  • February 20, 2026

    BioNTech Says Moderna's New COVID Vax Infringes Its IP

    BioNTech has launched a new patent infringement suit against Moderna, claiming that the rival's newer COVID-19 vaccine exploits BioNTech's "streamlined, domain-based" vaccine technology, according to a complaint filed in Delaware federal court.

  • February 20, 2026

    Dallas Jury Finds Ex-NFL Player Ran $328M Medicare Scheme

    A federal jury in Dallas has found that former NFL player and Texas laboratory owner Keith Gray orchestrated a $328 million fraud scheme involving billing for cardiovascular genetic testing, federal prosecutors said Thursday.

  • February 20, 2026

    Fertility Doctors Beat Patient's Embryo Loss Case

    A Connecticut woman waited too long to sue her fertility doctors over the loss of her frozen embryos after treatments in 2005 and 2006, a state court judge ruled Thursday, granting judgment to the doctors.

  • February 20, 2026

    Fed. Circ. Unwinds Ineligibility Ruling For Gene Therapy IP

    The Federal Circuit on Friday saved Regenxbio and the University of Pennsylvania's gene therapy patent, finding that splicing together genes from different organisms results in a molecule that is "markedly different from anything occurring in nature," rendering the therapy patent eligible. 

  • February 20, 2026

    Merck Wants Out Of Ex-Workers' Wage, ADA Suit

    Merck urged a North Carolina federal court on Friday to dismiss a former manufacturing facility employee's proposed class and collective action, arguing federal wage law bars his state overtime claim and that he failed to link his firing to sleep apnea.

  • February 20, 2026

    Chinese Chemical Imports Evading Duties, Commerce Says

    The U.S. Department of Commerce determined Friday that Chinese imports of a water treatment chemical into the U.S. are skirting antidumping and countervailing duties against such products after a U.S. company accused the countrywide industry of making misleading "minor" alterations.

  • February 20, 2026

    Beasley Allen Can't Pause NJ Talc DQ Order, Judge Rules

    The Beasley Allen Law Firm can't delay an order disqualifying it from representing hundreds of women who claim their ovarian cancer was caused by Johnson & Johnson's talcum powder while it seeks review from the New Jersey Supreme Court, a state judge ruled on Friday.

  • February 20, 2026

    Judge Says Texas Can't Enforce Optometry Anti-Steering Law

    A Texas federal judge on Friday blocked the state from enforcing an anti-steering law that banned managed care plans from telling insureds about optometrists who offer cheaper options, saying that the law violated protected commercial speech. 

  • February 20, 2026

    US Hits Pill Capsules From 4 Countries With Duty Orders

    The U.S. Department of Commerce hit empty pill capsules from China, India, Brazil and Vietnam imported into the U.S. with antidumping and countervailing duty orders, with some of the rates stretching higher than 77%.

  • February 20, 2026

    Taxation With Representation: Freshfields, Simpson Thacher

    In this week's Taxation With Representation, science and technology company Danaher Corp. acquires medical technology company Masimo Corp., Covetrus merges with a unit of fellow animal health technology company Cencora, and private equity firm Leonard Green & Partners LP buys outstanding Mister Car Wash Inc. shares not already owned by LGP affiliates.

  • February 19, 2026

    Judge Denies Mylan And Aurobindo's Bid To Escape Trial

    A Connecticut federal judge has once again rejected generic-drug makers' bid to escape a multistate lawsuit accusing them of engaging in an overarching antitrust conspiracy, saying the evidence supports the need for a jury trial on whether the companies colluded to fix prices and divvy up markets for dozens of generic drugs.

  • February 19, 2026

    Texas Suit Says Sanofi Paid Kickbacks For Prescriptions

    Texas Attorney General Ken Paxton sued Sanofi-Aventis US LLC in state court Thursday, accusing the pharmaceutical company of paying kickbacks to providers so they would prescribe Sanofi's drugs.

  • February 19, 2026

    Justices Urged To Bar Passive Infringement For Skinny Labels

    The Federal Circuit cleared the path for branded-drug makers to claim a rival induced infringement of a patent without taking any active steps to do so, Hikma told the U.S. Supreme Court in a case over so-called skinny labels.

  • February 19, 2026

    Judge Affirms Literal Infringement In Ravgen's $57M Jury Win

    A Texas federal judge has upheld a jury's finding that genetic testing company Natera Inc. committed literal infringement of a patent held by Ravgen Inc., but said Ravgen's expert testimony wasn't enough to support the jury's finding of infringement under the doctrine of equivalents.

  • February 19, 2026

    Red State AGs Back La. Bid To Halt Eased Abortion Pill Rules

    A coalition of 21 Republican state attorneys general, led by Nebraska, urged a federal judge to grant Louisiana's bid to block the U.S. Food and Drug Administration's 2023 rules easing access to the abortion drug mifepristone, arguing that the policy undermines states' authority to enforce their own abortion laws and imposes a "pocketbook injury" on states.

Expert Analysis

  • 9th Circ. Ruling May Help Pharma Cos. Avert Investor Claims

    Author Photo

    The Ninth Circuit's recent decision affirming the dismissal of a securities fraud class action alleging that Talphera deceived investors by marketing a drug with a misleading slogan should give plaintiffs pause before filing similar complaints where snappy slogans are accompanied by copious clarifying information, say attorneys at Simpson Thacher.

  • What Ethics Rules Say On Atty Discipline For Online Speech

    Author Photo

    Though law firms are free to discipline employees for their online commentary about Charlie Kirk or other social media activity, saying crude or insensitive things on the internet generally doesn’t subject attorneys to professional discipline under the Model Rules of Professional Conduct, says Stacie H. Rosenzweig at Halling & Cayo.

  • Junior Attys Must Beware Of 5 Common Legal Brief Mistakes

    Excerpt from Practical Guidance
    Author Photo

    Junior law firm associates must be careful to avoid five common pitfalls when drafting legal briefs — from including every possible argument to not developing a theme — to build the reputation of a sought-after litigator, says James Argionis at Cozen O'Connor.

  • Opinion

    State AGs, Not Local Officials, Should Lead Public Litigation

    Author Photo

    Local governments’ public nuisance lawsuits can raise constitutional and jurisdictional challenges, reinforcing the principle that state attorneys general — not municipalities — are best positioned to litigate on behalf of citizens when it is warranted, says former Utah Attorney General John Swallow.

  • 3rd Circ. Clarifies Ch. 11 3rd-Party Liability Scope Post-Purdue

    Author Photo

    A recent Third Circuit decision that tort claims against the purchaser of a debtor's business belong to the debtor's bankruptcy estate reinvigorates the use of Chapter 11 for the resolution of nondebtor liability in mass tort bankruptcies following last year's U.S. Supreme Court ruling in Purdue Pharma, say attorneys at Sullivan & Cromwell.

  • Texas Suit Marks Renewed Focus On Service Kickback Theory

    Author Photo

    After a dormant period at the federal level, a theory of kickback enforcement surrounding nurse educator programs and patient support services resurfaced with a recent state court complaint filed by Texas against Eli Lilly, highlighting for drugmakers the ever-changing nature of enforcement priorities and industry landscapes, say attorneys at Sheppard Mullin.

  • Series

    Power To The Paralegals: How And Why Training Must Evolve

    Author Photo

    Empowering paralegals through new models of education that emphasize digital fluency, interdisciplinary collaboration and human-centered lawyering could help solve workforce challenges and the justice gap — if firms, educators and policymakers get on board, say Kristine Custodio Suero and Kelli Radnothy.

  • Series

    Playing Softball Makes Me A Better Lawyer

    Author Photo

    My time on the softball field has taught me lessons that also apply to success in legal work — on effective preparation, flexibility, communication and teamwork, says Sarah Abrams at Baleen Specialty.

  • 5 Years In, COVID-19 Fraud Enforcement Landscape Is Shifting

    Author Photo

    As the government moves pandemic fraud enforcement from small-dollar individual prosecutions to high-value corporate cases, and billions of dollars remain unaccounted for, companies and defense attorneys must take steps now to prepare for the next five years of scrutiny, says attorney David Tarras.

  • Fed. Circ. In August: A Framework For AIA Derivation Disputes

    Author Photo

    In Global Health Solutions v. Selner, the Federal Circuit established how to assess derivation challenges under the America Invents Act's first-to-file system, making it easier for petitioners to determine a challenge's odds of success, say attorneys at Knobbe Martens.

  • USPTO's Track One A Reliable Patent Pathway Amid Backlog

    Author Photo

    As the U.S. Patent and Trademark Office faces a backlog of unexamined utility, plant and reissue patent applications, patent applicants should consider utilizing the USPTO's Track One Program, which not only expedites the process but also increases the likelihood of working with more senior examiners, says Ryan Schermerhorn at Marshall Gerstein.

  • Vanda Ruling Opens Door For Contesting FDA Drug Denials

    Author Photo

    The D.C. Circuit's recent decision in Vanda Pharmaceuticals v. U.S. Food and Drug Administration creates new opportunities and considerations for drug companies navigating the FDA approval process, establishing that litigation is an option when the FDA refuses to hold a hearing, say attorneys at Polsinelli.

  • Series

    Law School's Missed Lessons: Mastering Time Management

    Author Photo

    Law students typically have weeks or months to prepare for any given deadline, but the unpredictability of practicing in the real world means that lawyers must become time-management pros, ready to adapt to scheduling conflicts and unexpected assignments at any given moment, says David Thomas at Honigman.

  • Rare Del. Oversight Ruling Sends Governance Wake-Up Call

    Author Photo

    An unusual ruling from the Delaware Court of Chancery recently allowed Caremark oversight claims to proceed against former executives of a company previously known as Teligent, sending a clear reminder that boards and officers must actively monitor and document oversight efforts when addressing mission-critical risks, say attorneys at WilmerHale.

  • How Hyperlinks Are Changing E-Discovery Responsibilities

    Author Photo

    A recent e-discovery dispute over hyperlinked data in Hubbard v. Crow shows how courts have increasingly broadened the definition of control to account for cloud-based evidence, and why organizations must rethink preservation practices to avoid spoliation risks, says Bree Murphy at Exterro.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.